The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options
Open accessAbstract
The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) —a homologue of ACE—to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin–angiotensin–aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 3×
“Approximately 75% of patients in the early Chinese cohort received antiviral therapy.(6,32,43,115) The Italian recommendation is to commence treatment with antiviral therapy when COVID-19 is confirmed in patients with mild symptoms but not in a high mortality risk category or with moderate/severe signs of infection.”
BackgroundA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004973 · Cited by 9,951 · cited 1×
“SARS-CoV-2 is more stable on plastic and stainless steel than on copper and cardboard, and viable virus may be detected up to 72 h after application to these surfaces.(14) Patients with severe COVID-19 tend to have a high viral load and a long virus-shedding period.”
Background
Cited by
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Self-citationAssociation of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases
Lindner, D., Fitzek, A., Bräuninger, H., Aleshcheva, G., Edler, C., Meissner, K., Scherschel, K., Kirchhof, P., Escher, F., Schultheiss, H.-P., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.3551 · Cited by 827
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
McGonagle, D., O'Donnell, J. S., Sharif, K., Emery, P., & Bridgewood, C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30121-1 · Cited by 824
The COVID-19 pandemic: a global health crisis
Pollard, C. A., Morran, M. P., & Nestor-Kalinoski, A. L. (2020) · Physiological Genomics · doi:10.1152/physiolgenomics.00089.2020 · Cited by 514
Buzhdygan, T. P., DeOre, B. J., Baldwin-Leclair, A., Bullock, T. A., McGary, H. M., Khan, J. A., Razmpour, R., Hale, J. F., Galie, P. A., Potula, R., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105131 · Cited by 507
Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19
Rosenthal, N., Cao, Z., Gundrum, J., Sianis, J., & Safo, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29058 · Cited by 484
Regional and global contributions of air pollution to risk of death from COVID-19
Pozzer, A., Dominici, F., Haines, A., Witt, C., Münzel, T., & Lelieveld, J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa288 · Cited by 463
“47,48 Recent studies in China, the USA, as well as Europe indicate that patients with cardiovascular risk factors or established cardiovascular disease and other comorbid conditions are predisposed to myocardial injury during the course of COVID-19.”
BackgroundInfluentialXu, S.-W., Ilyas, I., & Weng, J.-P. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 440
COVID-19 and multiorgan failure: A narrative review on potential mechanisms
Mokhtari, T., Hassani, F., Ghaffari, N., Ebrahimi, B., Yarahmadi, A., & Hassanzadeh, G. (2020) · Journal of Molecular Histology · doi:10.1007/s10735-020-09915-3 · Cited by 439
Chest CT in COVID-19: What the Radiologist Needs to Know
Kwee, T. C., & Kwee, R. M. (2020) · RadioGraphics · doi:10.1148/rg.2020200159 · Cited by 438
Evans, P. C., Rainger, G. E., Mason, J. C., Guzik, T. J., Osto, E., Stamataki, Z., Neil, D., Hoefer, I. E., Fragiadaki, M., Waltenberger, J., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa230 · Cited by 437
Self-citationLong-term complications of COVID-19
Desai, A. D., Lavelle, M., Boursiquot, B. C., & Wan, E. Y. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00375.2021 · Cited by 415
COVID-19: from an acute to chronic disease? Potential long-term health consequences
Higgins, V., Sohaei, D., Diamandis, E. P., & Prassas, I. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1860895 · Cited by 405
Covid-19 and the cardiovascular system: a comprehensive review
Azevedo, R. B., Botelho, B. G., Hollanda, J. V. G. D., Ferreira, L. V. L., Junqueira de Andrade, L. Z., Oei, S. S. M. L., Mello, T. D. S., & Muxfeldt, E. S. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-0387-4 · Cited by 364
Bussani, R., Schneider, E., Zentilin, L., Collesi, C., Ali, H., Braga, L., Volpe, M. C., Colliva, A., Zanconati, F., Berlot, G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103104 · Cited by 358
Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L. I., Netti, L., Montefusco, G., Chimenti, C., Lavalle, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218118 · Cited by 349
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?
Huertas, A., Montani, D., Savale, L., Pichon, J., Tu, L., Parent, F., Guignabert, C., & Humbert, M. (2020) · European Respiratory Journal · doi:10.1183/13993003.01634-2020 · Cited by 340
Bienvenu, L. A., Noonan, J., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 338
Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis
Noor, F. M., & Islam, M. M. (2020) · Journal of Community Health · doi:10.1007/s10900-020-00920-x · Cited by 301
Lai, P. H., Lancet, E. A., Weiden, M. D., Webber, M. P., Zeig-Owens, R., Hall, C. B., & Prezant, D. J. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2488 · Cited by 291
In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19
Schaefer, I.-M., Padera, R. F., Solomon, I. H., Kanjilal, S., Hammer, M. M., Hornick, J. L., & Sholl, L. M. (2020) · Modern Pathology · doi:10.1038/s41379-020-0595-z · Cited by 285
Tajbakhsh, A., Gheibi Hayat, S. M., Taghizadeh, H., Akbari, A., inabadi, M., Savardashtaki, A., Johnston, T. P., & Sahebkar, A. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822737 · Cited by 272
Samuel, R. M., Majd, H., Richter, M. N., Ghazizadeh, Z., Zekavat, S. M., Navickas, A., Ramirez, J. T., Asgharian, H., Simoneau, C. R., Bonser, L. R., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.11.009 · Cited by 261
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Dong, M., Zhang, J., Ma, X., Tan, J., Chen, L., Liu, S., Xin, Y., & Zhuang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110678 · Cited by 259
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes
Bojkova, D., Wagner, J. U. G., Shumliakivska, M., Aslan, G. S., Saleem, U., Hansen, A., Luxán, G., Günther, S., Pham, M. D., Krishnan, J., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa267 · Cited by 257
Thrombotic complications of COVID-19
Avila, J., Long, B., Holladay, D., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.09.065 · Cited by 143
“Myocardial injury without direct plaque rupture may also occur due to cytokine storm, hypoxic injury, coronary spasm, and endothelial or vascular injury [54,55].”
Kronenfeld, J. P., & Penedo, F. J. (2021) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa105 · Cited by 93
The neurobiology of SARS-CoV-2 infection
Meinhardt, J., Streit, S., Dittmayer, C., Manitius, R. V., Radbruch, H., & Heppner, F. L. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00769-8 · Cited by 64
Roadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
“…that increased the likelihood of death after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 191 , associated with cardiovascular complications such as arrhythmia, cardiac injury, myocarditis, HF, pulmonary embolism and disseminated intravascular coagulation 192 .”
Self-citationMa, Y., Lu, D., Bao, L., Qu, Y., Liu, J., Qi, X., Yu, L., Zhang, X., Qi, F., Lv, Q., et al. (2021) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12155 · Cited by 25
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Mohammed Sheata, I., Smith, S. R., Kamel, H., Varrassi, G., Imani, F., Dayani, A., Myrcik, D., Urits, I., Viswanath, O., & Taha, S. S. (2021) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.113752 · Cited by 16
Metadata
- Authors
- Guzik, T. J., Mohiddin, S. A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F. M., Madhur, M. S., Tomaszewski, M., Maffia, P., D’Acquisto, F., Nicklin, S. A., Marian, A. J., Nosalski, R., Murray, E. C., Guzik, B., Berry, C., Touyz, R. M., Kreutz, R., Wang, D. W., Bhella, D., Sagliocco, O., Crea, F., Thomson, E. C., & McInnes, I. B.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-30
- Volume
- 116
- Issue
- 10
- Pages
- 1666-1687
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W3022580747
- Cited by
- 1,440
- References
- 157
- FWCI
- 38.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.